Simulation study suggests BF-BOLD reduces overdose rates and enhances safety in Phase I trials compared to conventional designs.

This methodological proposal utilized a simulation study to evaluate the Backfill Bayesian Ordered Lattice Design (BF-BOLD) within the context of Phase I clinical trials. The study compared this backfilling approach against conventional Phase I trial designs to assess its impact on dose-finding processes. The population and specific sample size were not reported, as the evidence derives from simulation modeling rather than a clinical cohort.

The primary outcome focused on optimal biological dose (OBD) determination, with secondary outcomes including safety assessment, activity assessment, treatment sustainability, overdose rates, and the potential for the Recommended Phase II Dose (RP2D). Simulation results indicated that dose-finding trials utilizing backfilling enhance safety and activity assessments. Furthermore, the model predicted a reduction in overdose rates and an improvement in treatment sustainability.

Regarding the potential for efficacy, the simulation suggested that the RP2D potential is preserved when using the BF-BOLD approach. No specific adverse events, serious adverse events, discontinuations, or tolerability data were reported, as these metrics were not applicable to the simulation framework. The study did not report specific absolute numbers, p-values, or confidence intervals for the outcomes.

Key limitations include the reliance on simulation data rather than empirical clinical evidence, meaning direct causal inferences cannot be made. The population and follow-up details were not reported. Despite these constraints, the practice relevance remains significant, as backfill designs represent an important design approach for early phase trials aimed at optimizing safety and efficiency.